BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the adoption of its PURE EP™ systems by a leading healthcare institution across multiple states. This expansion follows the resumption of elective procedures, contributing to anticipated sales growth. With over 680 cases performed using the PURE EP™ System, which addresses various arrhythmias, the company accumulates vital data for its AI platform. CEO Kenneth L. Londoner expressed optimism about future sales and the acceptance of their technology among leading electrophysiologists.

BioSig Technologies (Nasdaq: BSGM) will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 3 PM ET. CEO Ken Londoner will share insights about the company’s PURE EP™ System, which enhances signal fidelity in electrophysiology. This system has been utilized by over 40 physicians in more than 600 patient cases across eight clinical sites. Interested parties can schedule one-on-one meetings and view the live webcast via the provided links.

BioSig Technologies, Inc. (NASDAQ: BSGM) has announced that the U.S. Patent Office allowed a utility patent for its PURE EP™ technology, focusing on noise-filtering methods for cardiac signals. This innovation is crucial for accurately diagnosing and treating cardiac arrhythmias, particularly atrial fibrillation, which affects over 6 million Americans. The company now holds 34 patents globally for its PURE EP™ technology, enhancing its competitive position in the medical technology market. This new patent complements its patent portfolio and will assist medical teams in improving patient outcomes.

BioSig Technologies (NASDAQ: BSGM) announced significant advances in its operations, including the first commercial sale of the PURE EP™ System to St. David’s HealthCare and over 643 patient cases conducted. The company is expanding its clinical reach with additional sites due to begin evaluations soon. Furthermore, BioSig is developing novel nerve sensing technology and artificial intelligence solutions in collaboration with Mayo Clinic. With a robust cash position of $28.3 million, BioSig is poised for growth and innovation in 2021.

BioSig Technologies, Inc. (Nasdaq: BSGM) will present at the Benzinga Biotech Small Cap Conference on March 24-25, 2021. Kenneth L. Londoner, Chairman and CEO, is scheduled to speak on March 25th at 12:20 PM ET. He will discuss recent milestones related to the PURE EP™ System, an advanced platform aimed at improving cardiac ablations. Over 40 physicians have utilized the system in more than 600 patient cases across eight clinical sites. One-on-one meetings with management can be scheduled through links provided in the release.

BioSig Technologies (Nasdaq: BSGM) has been invited to the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021. Kenneth L. Londoner, Chairman and CEO, will participate in a virtual fireside chat at 8:00 AM ET and is available for investor meetings. BioSig's PURE EP™ System enhances signal fidelity for cardiac ablation procedures, with over 38 physicians completing more than 580 cases across 7 clinical sites. A replay of the chat will be accessible for 90 days post-event.

BioSig Technologies, a medical technology firm, will present at the 33rd Annual Virtual ROTH Conference from March 15-17, 2021. CEO Kenneth L. Londoner will discuss the company's progress and provide an overview of BioSig's innovative PURE EP™ System, which improves ECG signal fidelity and has been used in over 580 patient cases by more than 38 physicians. The presentation will be accessible online starting March 10, 2021, and available for 90 days. The conference, featuring numerous companies, attracts institutional investors and analysts.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the allowance of a utility patent for its subsidiary NeuroClear Technologies, licensed from the Mayo Foundation. This patent focuses on methods to enhance hypertension treatment through electroporation. It complements BioSig's expanding portfolio of nine allowed patents and 16 pending patent applications related to their PURE EP™ System. The company aims to develop its N-SENSE™ platform to address neurological conditions, utilizing innovative sensing designs and algorithms.

BioSig Technologies has appointed Brenda Castrodad as the new head of its Human Resources department to support the demand for its PURE EP System. With experience in life sciences at both start-ups and Fortune 500 companies, she previously transformed HR at TissueTech and expanded HeartWare's workforce significantly. Castrodad's expertise is expected to enhance talent acquisition and employee engagement amidst BioSig's growth trajectory. CEO Kenneth L. Londoner expressed confidence in her ability to drive innovation and success within the company.